hotspot -WSS

hotspot

author：comprehensive 2025-09-29 16:33:11 - browse：9189

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Why Novartis is going to walk from its acquisition of MorphoSys

WSS

What’s missing from the debate over nursing home staff minimums

Surgery pushed Ben Carson to fame

Top private equity targets in 2023: cardiology, clinical trials, lasers

How to fix the rural physician shortage in the U.S.

Timeline: Key moments in fight for gay rights

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

leisure time

hotspot

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Cancer drug shortages should be causing more outrage

Unique patient identifier: Experts argue the benefits, pitfalls

Tori Bowie and the unacceptable rates of Black maternal death

How to fix the rural physician shortage in the U.S.

Walensky prepares to leave CDC — and Congress — behind

The thinking behind the controversial eating disorder chatbot Tessa

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Mom launches Girl Scout troop for LGBTQ youth in Texas

focus

AstraZeneca stays mum on Medicare drug pricing negotiations

Biogen nominates mother of director’s child to replace him on board

Cano Health’s bankruptcy is a warning for Medicare Advantage

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Medicare Advantage plans can’t deny care with AI, CMS warns

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

hotspot

entertainment

Wikipedia

knowledge